Jenny Albanese

Title: Jenny Albanese: Innovator in Monoclonal Antibodies

Introduction

Jenny Albanese is a prominent inventor based in South Lake Tahoe, California. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, her work focuses on enhancing the efficacy of therapeutic antibodies.

Latest Patents

Albanese's latest patents include innovative approaches to monoclonal antibodies against prostate-specific membrane antigen (PSMA) that lack fucosyl residues. These antibodies demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity compared to their fucosylated counterparts. The invention also encompasses host cells that express these anti-PSMA antibodies, which are deficient in fucosyl transferase. Furthermore, methods for utilizing these antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are provided.

Career Highlights

Jenny Albanese is associated with Medarex Inc., where she has been instrumental in advancing research in monoclonal antibody technology. Her work has the potential to significantly impact cancer treatment and improve patient outcomes.

Collaborations

Albanese collaborates with notable colleagues, including Josephine M Cardarelli and David B Passmore. These partnerships enhance the research and development efforts within her field.

Conclusion

Jenny Albanese's contributions to the field of monoclonal antibodies exemplify her innovative spirit and dedication to improving therapeutic options for patients. Her work continues to pave the way for advancements in cancer treatment.